StockData

Innospec vs Orion

IOSP and OEC side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IOSP and OEC compare

Innospec is the larger company, worth 8.8 times as much as Orion ($2.0B against $226M).

Innospec grew revenue faster over the last twelve months (4.7% versus 0.86% for Orion).

Both pay dividends: Innospec yields 2.2% and Orion 1.6%.

Innospec scores higher on the StockData Score (14 against 8 for Orion), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIOSPOEC
Size and price
Market cap$2.0B$226M
Share price$80.39$3.99
Change, 1 year7.4%−16.5%
Change, 5 years−7.9%−78.2%
Beta (5Y)0.861.06
Employees2,4501,650
StockData Score
Total score14 (better)8
Valuation score44
Growth score1 (better)0
Performance score1 (better)0
Health score6 (better)2
Dividend score22
Valuation
P/S1.1×0.1× (better)
P/B1.4×0.6× (better)
EV/EBITDA8.5×5.4× (better)
P/FCF–5.2×
FCF yield–19.3%
Fair value$109.30$25.42
Margin of safety26.5%84.3% (better)
Growth
Revenue growth (TTM)4.7% (better)0.86%
Revenue growth, 5Y average8.3%9.7% (better)
EPS growth, 5Y average32.1%–
Profitability
Gross margin27.7% (better)18.5%
Operating margin8.8% (better)4.0%
Net margin–−1.8%
FCF margin–2.4%
Return on equity–−8.1%
Return on invested capital12.4% (better)2.7%
Financial health
Debt / equity0.002.48 (better)
Net debt / EBITDA–4.30
Current ratio2.95 (better)1.06
Altman Z-score5.12 (better)1.44
Piotroski F-score–3
Dividends and buybacks
Dividend yield2.2% (better)1.6%
Years of dividend growth12 (better)0
Dividend growth, 5Y average10.5% (better)−16.7%
Buyback yield0.68% (better)0.35%
Shareholder yield2.9% (better)1.9%
Ownership
Held by institutions101%94.1%
Held by insiders1.6%4.1%
Insider net buying, 12 months−$874K–
Superinvestors holding–1
Short interest, % of float1.9%4.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.